Spinnaker Trust Purchases 296 Shares of Becton Dickinson and Co (BDX)

Spinnaker Trust boosted its position in Becton Dickinson and Co (NYSE:BDX) by 2.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 15,218 shares of the medical instruments supplier’s stock after purchasing an additional 296 shares during the period. Spinnaker Trust’s holdings in Becton Dickinson and were worth $3,428,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Alerus Financial NA lifted its position in shares of Becton Dickinson and by 19.1% during the 4th quarter. Alerus Financial NA now owns 25,250 shares of the medical instruments supplier’s stock valued at $5,689,000 after buying an additional 4,054 shares in the last quarter. LS Investment Advisors LLC lifted its position in shares of Becton Dickinson and by 6.9% during the 4th quarter. LS Investment Advisors LLC now owns 17,269 shares of the medical instruments supplier’s stock valued at $3,891,000 after buying an additional 1,114 shares in the last quarter. Grimes & Company Inc. lifted its position in shares of Becton Dickinson and by 17.1% during the 4th quarter. Grimes & Company Inc. now owns 1,056 shares of the medical instruments supplier’s stock valued at $238,000 after buying an additional 154 shares in the last quarter. Taylor Hoffman Wealth Management lifted its position in shares of Becton Dickinson and by 5.8% during the 4th quarter. Taylor Hoffman Wealth Management now owns 2,895 shares of the medical instruments supplier’s stock valued at $637,000 after buying an additional 159 shares in the last quarter. Finally, Franklin Parlapiano Turner & Welch LLC lifted its position in shares of Becton Dickinson and by 1.5% during the 4th quarter. Franklin Parlapiano Turner & Welch LLC now owns 25,017 shares of the medical instruments supplier’s stock valued at $5,637,000 after buying an additional 368 shares in the last quarter. Hedge funds and other institutional investors own 86.28% of the company’s stock.

In related news, SVP Charles R. Bodner sold 2,080 shares of the stock in a transaction on Friday, November 16th. The stock was sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the transaction, the senior vice president now directly owns 4,497 shares of the company’s stock, valued at approximately $1,105,497.51. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Ribo Alberto Mas sold 4,530 shares of the stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $237.01, for a total value of $1,073,655.30. Following the completion of the transaction, the executive vice president now directly owns 14,596 shares of the company’s stock, valued at $3,459,397.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,606 shares of company stock valued at $8,356,772. 0.12% of the stock is owned by corporate insiders.

A number of brokerages have recently issued reports on BDX. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Piper Jaffray Companies increased their target price on Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research report on Tuesday, February 5th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 target price on the stock in a research report on Tuesday, January 8th. Barclays began coverage on Becton Dickinson and in a research report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. Finally, Morgan Stanley decreased their target price on Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and a consensus price target of $253.17.

NYSE BDX traded up $0.13 during mid-day trading on Monday, hitting $242.34. The stock had a trading volume of 14,362 shares, compared to its average volume of 1,042,927. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97. The company has a market cap of $65.45 billion, a P/E ratio of 22.02, a P/E/G ratio of 1.70 and a beta of 1.23.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The firm had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the prior year, the company earned $2.48 EPS. The firm’s revenue was up 35.1% compared to the same quarter last year. As a group, sell-side analysts predict that Becton Dickinson and Co will post 12.1 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Investors of record on Friday, March 8th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.27%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

TRADEMARK VIOLATION WARNING: “Spinnaker Trust Purchases 296 Shares of Becton Dickinson and Co (BDX)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2019/02/11/spinnaker-trust-purchases-296-shares-of-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is a back-end load?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply